Americas

PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This report focuses on the results from a market assessment on Shigella vaccines for use in traveler and military populations. It aims to provide a better understanding of the size and specific segments of these markets, as well as an evaluation of the factors that may impact demand and utilization of these vaccines. The traveler and military markets are but one segment of a larger global Shigella vaccine market which has enormous potential to impact global health among children and adults in low- and middle-income countries.

Respiratory syncytial virus (RSV) is a major, under-recognized public health problem causing more severe respiratory infections and hospitalizations in infants and young children each year than any other pathogen—with no widely available interventions to prevent it. Now, promising new tools for early RSV disease prevention are close on the horizon and the chance to address this pervasive virus has never been better.To raise awareness, PATH and the World Health Organization are developing an evolving toolkit of communications materials that public health stakeholders and advocates can use to share information about RSV disease, forthcoming prevention tools, and delivery considerations. To learn more about the toolkit, visit the web page.Editable files are available upon request. Please contact us.

This fact sheet describes Chemistry, Manufacturing, and Controls (CMC) work at PATH. It covers what CMC is and why it's important, where we work, our capabilities, and how interested parties can reach out to us for collaboration opportunities.

This year’s annual report features our annual financial overview, a list of PATH’s funders and supporters, and our accomplishments in 2021.

The Novartis Foundation launched an online artificial intelligence (AI) in health maturity assessment tool to help decision-makers identify where to best invest resources to enable successful deployment of impactful AI solutions in health. The tool was initially rolled out to six countries in 2021 and 2022: Argentina, Brazil, Chile, Philippines, Uruguay, and Vietnam; using a collaborative process that engaged key stakeholder groups, including representatives from the ministry of health, international nongovernmental organizations, civil society, private sector, and health organizations.This white paper shares an overview of the experience these countries had in conducting the self assessment. It also articulates the themes that emerged across countries and the various recommendations made to further explore AI in health to help address the challenges health systems face.

Medical oxygen proved to be a lifesaving drug during the COVID-19 pandemic in the absence of a proven therapeutic solution for patients suffering from the infection. In May 2021, India's health infrastructure was overwhelmed by the caseload, with a lack of oxygen, manpower, drugs, and hospital beds. The most difficult challenge for the country was providing an adequate volume of medical oxygen for the most severely ill patients who were unable to breathe on their own.PATH, with its extensive experience in respiratory care management, responded quickly and played a critical role in strengthening the oxygen ecosystem at this critical juncture. It provided technical assistance in the installation and procurement of PSA oxygen generation plants and oxygen concentrators, as well as improved their readiness.Furthermore, in order to build capacity for long-term sustainability, PATH developed, translated, and disseminated high-quality, reliable, and ready-reference knowledge products, such as the Guidebook on Medical Oxygen Management, Oxygen Posters, Standard Operating Procedures, Checklists, Case Studies, and Success Stories on various aspects of the oxygen ecosystem.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.